Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers

Twenty (20) healthy male subjects will be enrolled and assigned to either XZK group or
Lovastatin group at a 1:1 ratio at one site in the USA.

Inclusion Criteria:

- Capable of giving informed consent and complying with study procedures;

- Male subjects between the ages of 18 and 50 years, inclusive;

- Considered healthy by the PI, based on a detailed medical history, physical
examination, clinical laboratory tests, 12-lead ECG and vital signs;

- Nonsmoker, defined as not having smoked or used any form of tobacco in more than 6
months before screening;

- Body Mass Index (BMI) of 19 to 32 kg/m2 inclusive and body weight not less than 50
mg;

- Willing and able to adhere to study restrictions and to be confined at the clinical
research center.

Exclusion Criteria:

- Clinically significant past history of gastrointestinal, cardiovascular,
musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic,
bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug
hypersensitivity;

- History or presence of malignancy other than adequately treated basal cell skin
cancer;

- Clinically relevant illness within one month prior to the screening visit or at
screening visit that may interfere with the conduct of this study;

- Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface
antigen (HBsAG) or hepatitis C antibody;

- A history of seizure. However, a history of febrile seizure is allowed;

- A hospital admission or major surgery within 30 days prior to screening;

- Participation in any other investigational drug trial within 30 days from the last
dosing of other trials to screening;

- A history of prescription drug abuse, or illicit drug use within 6 months prior to
screening;

- A history of alcohol abuse according to medical history within 6 months prior to
screening;

- A positive screen for alcohol, drugs of abuse;

- Tobacco use within 6 months prior to screening based on subject report;

- Subjects with hypersensitivity to lipid-lowering agents;

- Subjects who have participated in a previous clinical study of XZK;

- An unwillingness or inability to comply with food and beverage restrictions during
study participation;

- Donation or blood collection of more than 1 unit (approximately 450 ml) of blood (or
blood products) or acute loss of blood during the 90 days prior to screening;

- Use of prescription or over-the-counter (OTC) medications, and herbal (including St.
John's Wort, herbal teas, garlic extracts) within 14 days prior to dosing (Note: Use
of acetaminophen at < 3g/day is permitted until 24 hours prior to dosing).